Calliditas: Obtains positive feedback regarding study design

Research Note

2019-09-03

08:24

Calliditas this morning announced that it has received acceptance of a design change of the Part B of the pivotal Nefigard study, which will have a positive effect on the timeline and cost related to this confirmatory part of the study. The news does not affect the timeline for top-line data for the trial, which based on positive data may form the basis for an accelerated approval. We continue to expect top-line data in H2 2020.

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.